CU24400B1 - Una composición que comprende 2,3-dihidroimidazo[1,2-c]quinazolinas sustituidas - Google Patents
Una composición que comprende 2,3-dihidroimidazo[1,2-c]quinazolinas sustituidasInfo
- Publication number
- CU24400B1 CU24400B1 CU2015000140A CU20150140A CU24400B1 CU 24400 B1 CU24400 B1 CU 24400B1 CU 2015000140 A CU2015000140 A CU 2015000140A CU 20150140 A CU20150140 A CU 20150140A CU 24400 B1 CU24400 B1 CU 24400B1
- Authority
- CU
- Cuba
- Prior art keywords
- dihydroimidazo
- composition
- inhibitor
- kinazolins
- substituted
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 3
- RDSACQWTXKSHJT-NSHDSACASA-N n-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)-6-methoxyphenyl]-1-[(2s)-2,3-dihydroxypropyl]cyclopropane-1-sulfonamide Chemical compound C1CC1(C[C@H](O)CO)S(=O)(=O)NC=1C(OC)=CC(F)=C(F)C=1NC1=CC=C(I)C=C1F RDSACQWTXKSHJT-NSHDSACASA-N 0.000 abstract 3
- 239000013543 active substance Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 abstract 1
- NTTQCLSBWRKUIJ-UHFFFAOYSA-N 2,3-dihydroimidazo[1,2-c]quinazoline Chemical class C1=CC=C2C3=NCCN3C=NC2=C1 NTTQCLSBWRKUIJ-UHFFFAOYSA-N 0.000 abstract 1
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 abstract 1
- 108091007960 PI3Ks Proteins 0.000 abstract 1
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 abstract 1
- 229960001507 ibrutinib Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229950008933 refametinib Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
<p>La presente invención está relacionada con una composición, que comprende una combinación de: a) un compuesto del tipo 2,3-dihidroimidazo [1,2-c]quinazolinas de fórmula general:</p> <p>ESPACIO PARA FÓRMULA</p> <p>, o composiciones farmacéuticas que lo contienen, como único agente activo, y b) un agente activo adicional que se selecciona del grupo que consiste en el inhibidor selectivo de la PI3K DELTA GS-1101, el inhibidor de las BTK ibrutinib, el compuesto inhibidor de las IKK BAY B y el refametinib (BAY 86-9766, RDEA-119).</p>
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13162710 | 2013-04-08 | ||
| EP13184240 | 2013-09-13 | ||
| PCT/EP2014/056768 WO2014166820A1 (en) | 2013-04-08 | 2014-04-04 | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomas |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CU20150140A7 CU20150140A7 (es) | 2016-10-28 |
| CU24400B1 true CU24400B1 (es) | 2019-04-04 |
Family
ID=50439383
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU2015000140A CU24400B1 (es) | 2013-04-08 | 2014-04-04 | Una composición que comprende 2,3-dihidroimidazo[1,2-c]quinazolinas sustituidas |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US9999623B2 (es) |
| EP (1) | EP2983669B1 (es) |
| JP (1) | JP6368353B2 (es) |
| KR (1) | KR102304108B1 (es) |
| CN (1) | CN105263497B (es) |
| AP (1) | AP2015008750A0 (es) |
| AU (1) | AU2014253348B2 (es) |
| BR (1) | BR112015025304B1 (es) |
| CA (1) | CA2908776C (es) |
| CL (1) | CL2015002978A1 (es) |
| CR (1) | CR20150523A (es) |
| CU (1) | CU24400B1 (es) |
| DO (1) | DOP2015000256A (es) |
| EA (2) | EA031493B9 (es) |
| ES (1) | ES2708350T3 (es) |
| IL (1) | IL241543B (es) |
| JO (1) | JOP20140141B1 (es) |
| MX (1) | MX2015014171A (es) |
| MY (1) | MY192626A (es) |
| NI (1) | NI201500148A (es) |
| PE (1) | PE20151780A1 (es) |
| PH (1) | PH12015502317A1 (es) |
| SG (2) | SG10201710539QA (es) |
| TN (1) | TN2015000452A1 (es) |
| TW (2) | TWI689307B (es) |
| UA (2) | UA119537C2 (es) |
| WO (1) | WO2014166820A1 (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2168583A1 (en) | 2008-09-24 | 2010-03-31 | Bayer Schering Pharma Aktiengesellschaft | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma |
| EP2508525A1 (en) * | 2011-04-05 | 2012-10-10 | Bayer Pharma Aktiengesellschaft | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts |
| WO2015082376A2 (en) * | 2013-12-03 | 2015-06-11 | Bayer Pharma Aktiengesellschaft | Use of pi3k-inhibitors |
| EP3077003A1 (en) | 2013-12-03 | 2016-10-12 | Bayer Pharma Aktiengesellschaft | Combination of pi3k-inhibitors |
| CN105017256A (zh) | 2014-04-29 | 2015-11-04 | 浙江导明医药科技有限公司 | 多氟化合物作为布鲁顿酪氨酸激酶抑制剂 |
| EP3018127A1 (en) | 2014-11-07 | 2016-05-11 | Bayer Pharma Aktiengesellschaft | Synthesis of copanlisib and its dihydrochloride salt |
| WO2016087490A1 (en) * | 2014-12-03 | 2016-06-09 | Bayer Pharma Aktiengesellschaft | Combination of pi3k-inhibitors |
| WO2016087488A1 (en) * | 2014-12-03 | 2016-06-09 | Bayer Pharma Aktiengesellschaft | Administration regime for aminoalcohol substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives |
| CN107864625B (zh) | 2015-03-09 | 2021-05-28 | 拜耳制药股份公司 | 含有取代的2,3-二氢咪唑并[1,2-c]喹唑啉的组合产品 |
| US9717745B2 (en) | 2015-03-19 | 2017-08-01 | Zhejiang DTRM Biopharma Co. Ltd. | Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases |
| WO2017002095A1 (en) | 2015-07-02 | 2017-01-05 | Acerta Pharma B.V. | Solid forms and formulations of (s)-4-(8-amino-3-(1 -(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide |
| JP2019512003A (ja) * | 2016-02-01 | 2019-05-09 | バイエル ファーマ アクチエンゲゼルシャフト | コパンリシブバイオマーカー |
| BR112018015782A2 (pt) * | 2016-02-01 | 2019-01-02 | Bayer Pharma AG | biomarcadores de copanlisibe |
| CA3016584A1 (en) | 2016-03-08 | 2017-09-14 | Bayer Pharma Aktiengesellschaft | 2-amino-n-[7-methoxy-2,3-dihydroimidazo-[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamides |
| EP3219329A1 (en) * | 2016-03-17 | 2017-09-20 | Bayer Pharma Aktiengesellschaft | Combinations of copanlisib |
| WO2017221092A1 (en) * | 2016-06-20 | 2017-12-28 | Novartis Ag | Triazolopyridine compounds and uses thereof |
| JP2019524872A (ja) * | 2016-06-20 | 2019-09-05 | ノバルティス アーゲー | 癌の治療に有用なイミダゾピリミジン化合物 |
| CN109729716B (zh) | 2016-09-23 | 2022-03-15 | 拜耳制药股份公司 | Pi3k-抑制剂的组合产品 |
| WO2018210296A1 (zh) | 2017-05-18 | 2018-11-22 | 江苏恒瑞医药股份有限公司 | 一种ezh2抑制剂与btk抑制剂联合在制备治疗肿瘤的药物中的用途 |
| EP3645005A1 (en) | 2017-06-28 | 2020-05-06 | Bayer Consumer Care AG | Combination of a pi3k-inhibitor with an androgen receptor antagonist |
| SG11202002356XA (en) | 2017-09-13 | 2020-04-29 | Guangdong Oppo Mobile Telecommunications Corp Ltd | Data processing method, terminal device and network device |
| TW201922256A (zh) | 2017-10-27 | 2019-06-16 | 中國大陸商浙江導明醫藥科技有限公司 | 治療淋巴樣惡性疾病之方法 |
| EP4045505A1 (en) * | 2019-10-15 | 2022-08-24 | Bayer Aktiengesellschaft | 2-methyl-aza-quinazolines |
| CN115120596A (zh) * | 2021-03-26 | 2022-09-30 | 上海璎黎药业有限公司 | 一种喹唑啉化合物及药物组合物的应用 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1400959A (en) | 1919-04-26 | 1921-12-20 | Ste Chim Usines Rhone | Process and apparatus for carrying out chemical reactions by catalysis |
| US1364099A (en) | 1919-09-10 | 1921-01-04 | Flannery Bolt Co | Staybolt structure for boilers |
| US1400975A (en) | 1920-10-11 | 1921-12-20 | Page Henry Benjiman | Dirigible headlight for motor-vehicles |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
| JP2003277383A (ja) | 2002-03-14 | 2003-10-02 | Bayer Ag | 光学活性ピリジン誘導体およびそれを含む医薬 |
| HRP20131159B1 (hr) | 2002-09-30 | 2019-11-01 | Bayer Ip Gmbh | Taljeni azol-pirimidin derivati |
| AR064106A1 (es) | 2006-12-05 | 2009-03-11 | Bayer Schering Pharma Ag | Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis |
| WO2009091550A2 (en) | 2008-01-14 | 2009-07-23 | Bayer Healthcare Llc | Sulfone substituted 2,3-dihydroimidazo [1,2-c] quinazoline derivatives useful for treating hyper-proliferative disorders and diseases with angiogenesis |
| EP2168583A1 (en) | 2008-09-24 | 2010-03-31 | Bayer Schering Pharma Aktiengesellschaft | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma |
| CA2796253A1 (en) | 2010-04-16 | 2011-10-20 | Bayer Intellectual Property Gmbh | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations |
| US9414370B2 (en) | 2010-05-14 | 2016-08-09 | Lg Electronics Inc. | Method for allocating resources in a wireless communication system and a device for the same |
| UA113280C2 (xx) * | 2010-11-11 | 2017-01-10 | АМІНОСПИРТЗАМІЩЕНІ ПОХІДНІ 2,3-ДИГІДРОІМІДАЗО$1,2-c]ХІНАЗОЛІНУ, ПРИДАТНІ ДЛЯ ЛІКУВАННЯ ГІПЕРПРОЛІФЕРАТИВНИХ ПОРУШЕНЬ І ЗАХВОРЮВАНЬ, ПОВ'ЯЗАНИХ З АНГІОГЕНЕЗОМ | |
| JP5790016B2 (ja) | 2011-02-18 | 2015-10-07 | コベルコ建機株式会社 | ハイブリッド建設機械 |
| BR112013014708B1 (pt) * | 2011-02-28 | 2021-10-19 | Sunshine Lake Pharma Co., Ltd. | Composto, composição farmacêutica, e, uso de um composto ou composição farmacêutica |
| WO2012121953A1 (en) * | 2011-03-08 | 2012-09-13 | The Trustees Of Columbia University In The City Of New York | Methods and pharmaceutical compositions for treating lymphoid malignancy |
| EP2508525A1 (en) | 2011-04-05 | 2012-10-10 | Bayer Pharma Aktiengesellschaft | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts |
| JO3733B1 (ar) | 2011-04-05 | 2021-01-31 | Bayer Ip Gmbh | استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة |
| US10465247B2 (en) * | 2011-07-01 | 2019-11-05 | Dana-Farber Cancer Institute, Inc. | Discovery of a somatic mutation in MYD88 gene in lymphoplasmacytic lymphoma |
| WO2013169858A1 (en) * | 2012-05-08 | 2013-11-14 | The Broad Institute, Inc. | Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy |
| US8993891B2 (en) | 2012-06-28 | 2015-03-31 | Thomas & Betts International, Inc. | Lift and pivot grommet |
| EP3077002B1 (en) | 2013-12-03 | 2020-04-22 | Bayer Pharma Aktiengesellschaft | Combination of pi3k-inhibitors |
| EP3018127A1 (en) | 2014-11-07 | 2016-05-11 | Bayer Pharma Aktiengesellschaft | Synthesis of copanlisib and its dihydrochloride salt |
| EP3018131A1 (en) | 2014-11-07 | 2016-05-11 | Bayer Pharma Aktiengesellschaft | Synthesis of copanlisib and its dihydrochloride salt |
| KR20180013850A (ko) | 2015-03-09 | 2018-02-07 | 바이엘 파마 악티엔게젤샤프트 | 치환된 2,3-디히드로이미다조[1,2-c]퀴나졸린의 용도 |
| CN107864625B (zh) | 2015-03-09 | 2021-05-28 | 拜耳制药股份公司 | 含有取代的2,3-二氢咪唑并[1,2-c]喹唑啉的组合产品 |
-
2014
- 2014-04-04 UA UAA201510750A patent/UA119537C2/uk unknown
- 2014-04-04 ES ES14715293T patent/ES2708350T3/es active Active
- 2014-04-04 TN TN2015000452A patent/TN2015000452A1/en unknown
- 2014-04-04 KR KR1020157031640A patent/KR102304108B1/ko not_active Expired - Fee Related
- 2014-04-04 AU AU2014253348A patent/AU2014253348B2/en not_active Ceased
- 2014-04-04 EP EP14715293.8A patent/EP2983669B1/en active Active
- 2014-04-04 PE PE2015002123A patent/PE20151780A1/es unknown
- 2014-04-04 CU CU2015000140A patent/CU24400B1/es unknown
- 2014-04-04 WO PCT/EP2014/056768 patent/WO2014166820A1/en not_active Ceased
- 2014-04-04 BR BR112015025304-0A patent/BR112015025304B1/pt not_active IP Right Cessation
- 2014-04-04 EA EA201591932A patent/EA031493B9/ru not_active IP Right Cessation
- 2014-04-04 EA EA201792650A patent/EA037577B1/ru unknown
- 2014-04-04 CN CN201480032696.4A patent/CN105263497B/zh not_active Expired - Fee Related
- 2014-04-04 AP AP2015008750A patent/AP2015008750A0/xx unknown
- 2014-04-04 JP JP2016505835A patent/JP6368353B2/ja not_active Expired - Fee Related
- 2014-04-04 US US14/781,224 patent/US9999623B2/en active Active
- 2014-04-04 SG SG10201710539QA patent/SG10201710539QA/en unknown
- 2014-04-04 UA UAA201812437A patent/UA122822C2/uk unknown
- 2014-04-04 MX MX2015014171A patent/MX2015014171A/es unknown
- 2014-04-04 CA CA2908776A patent/CA2908776C/en active Active
- 2014-04-04 MY MYPI2015703538A patent/MY192626A/en unknown
- 2014-04-04 SG SG11201507265XA patent/SG11201507265XA/en unknown
- 2014-04-06 JO JOP/2014/0141A patent/JOP20140141B1/ar active
- 2014-04-08 TW TW107134848A patent/TWI689307B/zh not_active IP Right Cessation
- 2014-04-08 TW TW103112877A patent/TWI675663B/zh not_active IP Right Cessation
-
2015
- 2015-09-10 IL IL241543A patent/IL241543B/en active IP Right Grant
- 2015-10-06 PH PH12015502317A patent/PH12015502317A1/en unknown
- 2015-10-07 CL CL2015002978A patent/CL2015002978A1/es unknown
- 2015-10-08 NI NI201500148A patent/NI201500148A/es unknown
- 2015-10-08 CR CR20150523A patent/CR20150523A/es unknown
- 2015-10-08 DO DO2015000256A patent/DOP2015000256A/es unknown
-
2018
- 2018-01-03 US US15/861,555 patent/US10226469B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CU24400B1 (es) | Una composición que comprende 2,3-dihidroimidazo[1,2-c]quinazolinas sustituidas | |
| MX2018015709A (es) | Derivados de azabencimidazol como inhibidores de pi3k beta. | |
| CL2018001031A1 (es) | Inhibidores de ferroportina novedosos | |
| NI201700135A (es) | Derivados de ciclohexano sustituido con amido | |
| UY35353A (es) | Un inhibidor de mdm2 derivado de ácido benzoico para el tratamiento del cáncer | |
| DOP2016000085A (es) | Amino-heteroaril-benzamidas como inhibidores de cinasa | |
| UY35237A (es) | Composiciones que comprenden un compuesto de triazol | |
| UY35238A (es) | Composiciones que comprenden un compuesto de triazol | |
| PE20151423A1 (es) | Derivados tetrahidropiranilo inhibidores del hcv | |
| CU20170162A7 (es) | Derivados de fenil-tieno(2,3-d)pirimidina-hidroxiácido útiles en el tratamiento del cáncer y enfermedades autoinmunes, método de preparación de los mismos y composiciones farmacéuticas que los contienen | |
| UY35040A (es) | Pirrolopirimidinilamino-benzotiazolonas sustituidas | |
| ECSP15030799A (es) | Compuestos sustituidos de pirrolopirimidina, composiciones de los mismos, y métodos de tratamiento con los mismos | |
| DOP2015000077A (es) | Derivados de pirrolotriazinona como inhibidores de pi3k | |
| DOP2020000100A (es) | Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3 | |
| CR20160433A (es) | Nuevos compuestos | |
| MX2018004304A (es) | DERIVADOS DE QUINOXALINA Y PIRIDOPRAZINA COMO INHIBIDORES DE PI3Kß. | |
| DOP2016000007A (es) | Pirazolpiridinas sustituidas | |
| SV2017005466A (es) | Pirazolpiridinaminas como inhibidores de mknk1 y mknk2 | |
| DOP2016000118A (es) | Tienopirimidinas como inhibidores mknk1 y mknk2 | |
| UY35332A (es) | Derivados de pirrolotriazina como inhibidores de pi3k | |
| PH12016501932A1 (en) | Amido-substituted azole compounds | |
| PE20151669A1 (es) | Compuestos de azetidiniloxifenilpirrolidina | |
| CR20160432A (es) | Inhibidores de las vías de señalización de wnt | |
| CO2019003761A2 (es) | Derivados sustituidos de 6-(1h-pirazol-1-il)pirimidin-4-amina y usos de los mismos | |
| MX2018015707A (es) | Derivados biciclicos de piridina, pirazina y pirimidina como inhibidores de pi3k beta. |